FDA Drug · D-0131-2025

Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-442-20

Class II · Ongoing

Subpotent and Superpotent Drug

Affected lots / codes — check yours against thisLot #: 3115936, Exp. Date 07/2025

Recalling firm: Mylan Institutional, Inc., Rockford, IL
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 2,835 cartons
Distribution: Nationwide in the USA.
Recall initiated: November 19, 2024
Classified: December 12, 2024
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0131-2025%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →